Aclaris Therapeutics Income Statement (2014-2026) | ACRS

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026	Jun2026
Revenue & cost
Revenue (Quarter)	1.66M	1.50M	1.45M	1.53M	19.02M	7.75M	2.53M	1.87M	9.28M	17.57M	2.40M	2.77M	4.35M	9.21M	1.46M	1.78M	3.30M	1.29M	2.00M	1.63M
Cost of Revenue (Quarter)	1.10M	1.15M	1.16M	1.07M	0.92M	0.88M	0.81M	1.04M	0.85M	0.72M	0.81M	0.62M	0.65M	0.70M	0.51M	0.52M	0.54M	0.53M	0.40M	0.22M
Gross Profit (Quarter)	0.56M	0.35M	0.30M	0.46M	18.09M	6.88M	1.72M	0.83M	8.43M	16.84M	1.59M	2.14M	3.69M	8.51M	0.95M	1.26M	2.76M	0.76M	1.60M	1.41M
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)	13.98M	14.10M	14.31M	18.78M	23.66M	21.07M	22.59M	25.27M	23.88M	26.65M	9.85M	8.76M	5.96M	9.03M	11.58M	11.45M	13.03M	16.58M	15.66M	18.07M
Selling, General & Administrative (Quarter)	5.98M	6.94M	6.10M	6.08M	5.81M	7.15M	8.79M	8.32M	7.09M	8.21M	6.84M	4.75M	5.65M	4.95M	6.14M	5.39M	4.87M	5.58M	6.74M	6.05M
Other Operating Expenses (Quarter)	2.00M	3.35M	-0.04M	-2.33M	10.42M	8.61M	1.07M	0.09M	9.89M	-13.24M	4.64M	2.11M	3.21M	94.91M	1.82M	3.35M	2.55M	1.87M	1.79M	1.75M
Operating Expenses (Quarter)	21.95M	24.39M	20.36M	22.52M	39.89M	36.83M	32.45M	33.68M	40.86M	21.62M	21.33M	15.62M	14.82M	108.89M	19.54M	20.18M	20.45M	24.03M	24.19M	25.87M
Operating Income (Quarter)	-20.30M	-22.89M	-18.91M	-20.99M	-20.87M	-29.08M	-29.92M	-31.82M	-31.58M	-4.05M	-18.93M	-12.85M	-10.47M	-99.67M	-18.08M	-18.41M	-17.15M	-22.73M	-22.19M	-24.24M
EBIT (Quarter)	-20.30M	-22.89M	-18.91M	-20.99M	-20.87M	-29.08M	-29.92M	-31.82M	-31.58M	-4.05M	-18.93M	-12.85M	-10.47M	-99.67M	-18.08M	-18.41M	-17.15M	-22.73M	-22.19M	-24.24M
Non-operating items
Interest & Investment Income (Quarter)	0.01M	-0.22M	-0.75M	-0.35M	-0.14M	0.57M	0.54M	-0.76M	2.32M	2.19M	1.99M	1.87M	0.89M	-5.65M	0.34M	0.05M	0.12M	0.01M	-0.59M	1.76M
Other Non Operating Income (Quarter)	-0.85M	0.09M	0.12M	0.46M	0.92M	1.44M	1.76M	2.25M	2.32M	2.19M	1.99M	1.87M
Non Operating Income (Quarter)									2.32M	2.19M	1.99M	1.87M	2.88M	3.12M	3.00M	2.98M	2.54M	2.94M	2.37M	2.73M
Net income details
EBT (Quarter)	-38.44M	-36.83M	-38.01M	-32.16M	-36.39M	-43.80M	-34.12M	-39.00M	-32.94M	-196.98M	-17.43M	-11.46M	-9.66M	-108.29M	-18.49M	-18.87M	-19.19M	-31.32M	-37.46M	-54.91M
Profit After Tax (Quarter)	-20.96M	-22.93M	-18.79M	-20.53M	-19.95M	-26.39M	-28.16M	-29.57M	-29.28M	-0.70M	-16.94M	-10.99M	-7.59M	-96.55M	-14.75M	-15.43M	-14.50M	-19.80M	-19.82M	-21.83M
Income from Continuing Operations (Quarter)	-38.44M	-36.83M	-38.01M	-32.16M	-36.39M	-43.80M	-34.12M	-39.00M	-32.94M	-196.98M	-17.43M	-11.46M	-9.66M	-108.29M	-18.49M	-18.87M	-19.19M	-31.32M	-37.46M	-54.91M
Consolidated Net Income (Quarter)	-38.44M	-36.83M	-38.01M	-32.16M	-36.39M	-43.80M	-34.12M	-39.00M	-32.94M	-196.98M	-17.43M	-11.46M	-9.66M	-108.29M	-18.49M	-18.87M	-19.19M	-31.32M	-37.46M	-54.91M
Income towards Parent Company (Quarter)	-38.44M	-36.83M	-38.01M	-32.16M	-36.39M	-43.80M	-34.12M	-39.00M	-32.94M	-196.98M	-17.43M	-11.46M	-9.66M	-108.29M	-18.49M	-18.87M	-19.19M	-31.32M	-37.46M	-54.91M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-38.44M	-36.83M	-38.01M	-32.16M	-36.39M	-43.80M	-34.12M	-39.00M	-32.94M	-196.98M	-17.43M	-11.46M	-9.66M	-108.29M	-18.49M	-18.87M	-19.19M	-31.32M	-37.46M	-54.91M
Additional items
EPS (Basic) (Quarter)	-0.63	-0.65	-0.62	-0.49	-0.55	-0.67	-0.51	-0.55	-0.47	-2.82	-0.25	-0.16	-0.14	-1.40	-0.15	-0.15	-0.16	-0.26	-0.29	-0.38
EPS (Diluted) (Quarter)	-0.63	-0.65	-0.62	-0.49	-0.55	-0.67	-0.51	-0.55	-0.47	-2.82	-0.25	-0.16	-0.14	-1.40	-0.15	-0.15	-0.16	-0.26	-0.29	-0.38
Shares Outstanding (Quarter)	61.22M	56.73M	61.43M	65.99M	66.68M	65.21M	66.87M	70.63M	70.81M	69.81M	71.07M	71.29M	71.38M	77.30M	122.39M	122.58M	122.62M	122.56M	128.81M	142.74M
Shares Outstanding (Diluted) (Quarter)	61.22M	56.73M	61.43M	65.99M	66.68M	65.21M	66.87M	70.63M	70.81M	69.81M	71.07M	71.29M	71.38M	77.30M	122.39M	122.58M	122.62M	122.56M	128.81M	142.74M
Shares Outstanding (Entity) (Quarter)	61.23M	61.23M	61.74M	66.67M	66.68M	66.69M	67.21M	70.77M	70.82M	70.89M	71.25M	71.33M	71.42M	77.30M	108.27M	108.33M	108.34M	120.50M	139.65M	139.82M
EBITDA (Quarter)	-20.30M	-22.89M	-18.91M	-20.99M	-20.87M	-29.08M	-29.92M	-31.82M	-31.58M	-4.05M	-18.93M	-12.85M	-10.47M	-99.67M	-18.08M	-18.41M	-17.15M	-22.73M	-22.19M	-24.24M
Interest Expenses (Quarter)	18.15M	13.71M	18.36M	10.82M	15.38M	15.29M	4.74M	6.43M	3.68M	195.12M	0.49M	0.48M	0.08M	2.97M	0.74M	0.51M	2.16M	8.60M	14.68M	32.43M

Research Tools

Datasets

Plans

Developers

Aclaris Therapeutics Income Statement (2014-2026) | ACRS

Research Tools

Datasets

Plans

Developers

Aclaris Therapeutics Income Statement (2014-2026) | ACRS

Create an account

Sign In

Reset Password